Posters

      Differences in Perceived Health Risk of Cigarettes and IQOS® by Current Product Use Categories and Intention to Quit: A Cross-Sectional Study in Japan

      Spies, E.; Dobrynina, M.; Kallischnigg, G.; M-Zwisele, M-S. Zwisele.; Chrea, C.; Prieto, L.; Langer, P.; Weitkunat, R.

      Conference date
      Feb 22, 2019
      Conference name
      Society for Research on Nicotine and Tobacco (SRNT) 2019
      Link to more information
      Topic
      Summary

      Background: Smoking cigarettes remains a leading cause of preventable deaths. Although quitting smoking is best way of reducing health risks, reduced-risk tobacco products (RRP) are being developed as alternatives for current adult smokers. Understanding the risk perceptions associated with RRPs may help create appropriate communications to facilitate harm reduction. This study examined risk perceptions of IQOS, a potential RRP, and conventional cigarettes (CC) by tobacco use and behavioral intentions. Methods: The current study pooled data from three waves of an online, cross-sectional survey conducted among a convenience sample of IQOS users (N=1,500) registered in the product’s database in Japan. Descriptive analyses were completed to visualize data. A multiple linear regression examined the relationship between tobacco use and behavioral intentions with perceived health risk. Results: A total of 1,323 IQOS users were included in this analysis. The majority were males (81.9%) aged 30–49 (65.2%). Nearly two-thirds of participants reported using IQOS exclusively, while 20.3% reported using both IQOS and CC. Slightly more than one-third of participants reported an intention to quit all tobacco. In the final regression model examining the difference in perceived health risk between CC and IQOS (CC-IQOS), females and those aged 40–49 perceived a statistically significantly greater difference of risk; poly-users (inclusive of IQOS and CC) perceived a significantly lower difference. Conclusions: Based on these findings, to facilitate harm reduction behaviors, messages explaining risk reduction may need to be tailored on the basis of biological sex, age, and type of tobacco use.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.